...
首页> 外文期刊>The Indian journal of medical research >Initial trends of individual donation nucleic acid testing in voluntary & replacement donors from a tertiary care centre in north India
【24h】

Initial trends of individual donation nucleic acid testing in voluntary & replacement donors from a tertiary care centre in north India

机译:印度北部三级医疗中心的自愿和替代供体中个人捐赠核酸检测的初步趋势

获取原文

摘要

Background & objectives: Individual donation nucleic acid testing (ID-NAT) is considered as sensitive technology to assess blood safety from viral transfusion-transmissible infections (TTIs) in blood donors. The present study was aimed to analyze the results of ID-NAT for three years (2013-2015) with special reference to different types of donors and their age ranges in a tertiary care centre in north India. Methods: The results of ID-NAT for three years were retrospectively analyzed at our centre. A total of 168,433 donations were tested with ID-NAT, of which 10,467 were tested with Procleixsup?/sup Ultriosup?/sup reagents and 157,966 were tested with Procleixsup?/supUltrioPlussup?/sup reagents, and the results were compared with those of serology to calculate the NAT yield in voluntary, replacement, first-time and repeat donors. Results: A combined NAT yield was observed as one in 1031 out of 167,069 seronegative donations with HBV yield as one in 1465, HCV yield as one in 3885 and HIV-1 as one in 167,069. Yield for co-infection (HCV and HBV) was one in 41,767. A high NAT yield was observed in replacement donors (1 in 498) as compared to voluntary donors (1 in 1320). Interpretation & conclusions: Addition of NAT to serology improved the blood safety in our centre interdicting possibility of 150 TTIs annually. It has also reemphasized the safety of voluntary over replacement donors. The results also highlight the need of proper counselling, notification and referral guidelines of NAT yield donors in our country and other countries which lack them.
机译:背景与目的:个人捐赠核酸检测(ID-NAT)被认为是评估献血者血液中病毒输血传播性感染(TTI)的血液安全性的敏感技术。本研究旨在分析ID-NAT三年(2013-2015年)的结果,并特别参考印度北部三级医疗中心的不同类型的捐助者及其年龄范围。方法:对我中心三年来ID-NAT的结果进行回顾性分析。总共168,433个捐赠用ID-NAT测试,其中10,467个使用Procleix ? Ultrio ?试剂测试,157,966个使用Procleix 测试。 > UltrioPlus ?试剂,并将结果与​​血清学结果进行比较,以计算自愿,替代,首次和重复供体的NAT产量。结果:在167,069例血清阴性捐赠中,NAT的总产量为1031分之一,其中HBV产量为1465分之一,HCV产量为3885分之一,HIV-1为167,069分之一。共感染(HCV和HBV)的产率为41,767分之一。与自愿捐赠者(1320名中的1名)相比,替代捐赠者中的NAT产量高(498名中的1名)。解释与结论:在血清学中添加NAT可改善我们中心的血液安全性,从而阻止了每年150例TTI的发生。它还强调了自愿替代替代捐助者的安全性。研究结果还强调,在我们国家和其他国家中,需要适当的NAT产量捐献者咨询,通知和转介指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号